Medicare Part D’s ‘Catastrophic Cliff’ Slows Eliquis, Trulicity Sales In Third Quarter
Executive Summary
Pfizer, BMS and Lilly see sales impacted by Part D changes that leave some beneficiaries in the coverage gap longer this year, extending manufacturer discount obligations.